Thomas Braun

Dr. Thomas Braun

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Controlled Clinical Trials
Verified
Journal Article
Closed access
TBThomas Braun
Thomas Braun

27 September 2011 in Biometrics
Verified
Journal Article
Closed access
PDF file
OLOliver E. Lee
Oliver E. Lee
TBThomas Braun
Thomas Braun

30 November 2009 in Biometrics
Verified
Journal Article
Closed access
PDF file
TBThomas Braun
Thomas Braun
SWShufang Wang
Shufang Wang

1 April 2007 in Clinical Trials
Verified
Journal Article
Closed access
PDF file
TBThomas Braun
Thomas Braun
PTPeter F. Thall
Peter F. Thall
HNHoang Nguyen
Hoang Nguyen
MLMarcos de Lima
Marcos de Lima
Background Traditionally, phase I clinical trial designs are based upon one predefined course of treatment while varying among patients the dose given at each administration. In actual medical practice, patients receive a schedule comprised of several courses of treatment, and some patients may receive one or more dose reductions or delays during treatment. Consequently, the overall risk of toxicity for each patient is a function of both actual schedule of treatment and the differing doses used at each adminstration.

11 October 2005 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
TBThomas Braun
Thomas Braun

27 October 2020 in Sensors
Verified
Journal Article
Open access
PDF file
Vibhuti GuptaVibhuti Gupta
Vibhuti Gupta
TBThomas Braun
Thomas Braun
MCMosharaf Chowdhury
Mosharaf Chowdhury
MTMuneesh Tewari
Muneesh Tewari
SCSung Won Choi
Sung Won Choi
Machine learning techniques are widely used nowadays in the healthcare domain for the diagnosis, prognosis, and treatment of diseases. These techniques have applications in the field of hematopoietic cell transplantation (HCT), which is a potentially curative therapy for hematological malignancies. Herein, a systematic review of the application of machine learning (ML) techniques in the HCT setting was conducted. We examined the type of data streams included, specific ML techniques used, and type of clinical outcomes measured. A systematic review of English articles using PubMed, Scopus, Web of Science, and IEEE Xplore databases was performed. Search terms included “hematopoietic cell transplantation (HCT),” “autologous HCT,” “allogeneic HCT,” “machine learning,” and “artificial intelligence.” Only full-text studies reported between January 2015 and July 2020 were included. Data were extracted by two authors using predefined data fields. Following PRISMA guidelines, a total of 242 studies were identified, of which 27 studies met the inclusion criteria. These studies were sub-categorized into three broad topics and the type of ML techniques used included ensemble learning (63%), regression (44%), Bayesian learning (30%), and support vector machine (30%). The majority of studies examined models to predict HCT outcomes (e.g., survival, relapse, graft-versus-host disease). Clinical and genetic data were the most commonly used predictors in the modeling process. Overall, this review provided a systematic review of ML techniques applied in the context of HCT. The evidence is not sufficiently robust to determine the optimal ML technique to use in the HCT setting and/or what minimal data variables are required.